Zynerba Pharmaceuticals Initiates Phase 1 Clinical Trial for ZYN002 CBD Gel

By: via Benzinga
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) today announced the initiation of a Phase 1 clinical trial for its ZYN002 cannabidiol (CBD) ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.